Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 Jan 15;90(2):457–461. doi: 10.1073/pnas.90.2.457

Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.

M Better 1, S L Bernhard 1, S P Lei 1, D M Fishwild 1, J A Lane 1, S F Carroll 1, A H Horwitz 1
PMCID: PMC45682  PMID: 7678457

Abstract

We have used genetic engineering to obtain secretion of anti-human CD5 antibody fragments from Escherichia coli for conjugation to the 30-kDa form of ricin A chain (RTA30). This was accomplished by introducing stop codons at two positions in the hinge region of the human IgG1 gene so that coexpression of the truncated heavy-chain genes (Fd') with a light chain would result in Fab' and/or F(ab')2 proteins containing either one or two interheavy-chain cysteines. An Fd' gene encoding both interheavy-chain cysteines yielded a mixture of F(ab')2 and Fab', which could be separated by size-exclusion chromatography. An Fd' gene encoding only one interheavy-chain cysteine yielded primarily Fab'. Purified F(ab')2 protein was equivalent to unlabeled chimeric IgG in competing for binding of IgG with CD5 antigen, while the molar concentration of the monovalent Fab' required for 50% binding inhibition was 4- to 5-fold higher than IgG. An immunoconjugate was prepared with Fab' by direct coupling to the unique free cysteine on RTA30. The bivalent F(ab')2 was conjugated to RTA30 after derivatization with the crosslinking agent 5-methyl-2-iminothiolane. These immunoconjugates efficiently killed a CD5+ T-cell line and human peripheral blood T cells.

Full text

PDF
457

Images in this article

459Image
on p.459
459Image
on p.459

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Better M., Chang C. P., Robinson R. R., Horwitz A. H. Escherichia coli secretion of an active chimeric antibody fragment. Science. 1988 May 20;240(4855):1041–1043. doi: 10.1126/science.3285471. [DOI] [PubMed] [Google Scholar]
  2. Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S. M., Lee T., Pope S. H., Riordan G. S., Whitlow M. Single-chain antigen-binding proteins. Science. 1988 Oct 21;242(4877):423–426. doi: 10.1126/science.3140379. [DOI] [PubMed] [Google Scholar]
  3. Blakey D. C., Wawrzynczak E. J., Wallace P. M., Thorpe P. E. Antibody toxin conjugates: a perspective. Prog Allergy. 1988;45:50–90. [PubMed] [Google Scholar]
  4. Buchner J., Rudolph R. Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology (N Y) 1991 Feb;9(2):157–162. doi: 10.1038/nbt0291-157. [DOI] [PubMed] [Google Scholar]
  5. Byers V. S., Henslee P. J., Kernan N. A., Blazar B. R., Gingrich R., Phillips G. L., LeMaistre C. F., Gilliland G., Antin J. H., Martin P. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood. 1990 Apr 1;75(7):1426–1432. [PubMed] [Google Scholar]
  6. Carter P., Kelley R. F., Rodrigues M. L., Snedecor B., Covarrubias M., Velligan M. D., Wong W. L., Rowland A. M., Kotts C. E., Carver M. E. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (N Y) 1992 Feb;10(2):163–167. doi: 10.1038/nbt0292-163. [DOI] [PubMed] [Google Scholar]
  7. Carteron N. L., Wofsy D., Schimenti C., Ermak T. H. F(ab')2 anti-CD4 and intact anti-CD4 monoclonal antibodies inhibit the accumulation of CD4+ T cells, CD8+ T cells, and B cells in the kidneys of lupus-prone NZB/NZW mice. Clin Immunol Immunopathol. 1990 Sep;56(3):373–383. doi: 10.1016/0090-1229(90)90157-l. [DOI] [PubMed] [Google Scholar]
  8. Chaudhary V. K., Queen C., Junghans R. P., Waldmann T. A., FitzGerald D. J., Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989 Jun 1;339(6223):394–397. doi: 10.1038/339394a0. [DOI] [PubMed] [Google Scholar]
  9. Chiron M., Derocq J. M., Kuhlein E., Roubinet F., Demur C., Grandjean H., Huguet F., Jaffrezou J. P., Jansen F., Laurent G. Sensitivity of fresh leukemic cells to T101 ricin A-chain immunotoxin: a comparative study between Fab fragment and whole Ig conjugates. Leuk Res. 1989;13(6):491–499. doi: 10.1016/0145-2126(89)90171-9. [DOI] [PubMed] [Google Scholar]
  10. Chovnick A., Schneider W. P., Tso J. Y., Queen C., Chang C. N. A recombinant, membrane-acting immunotoxin. Cancer Res. 1991 Jan 15;51(2):465–467. [PubMed] [Google Scholar]
  11. Colapinto E. V., Humphrey P. A., Zalutsky M. R., Groothuis D. R., Friedman H. S., de Tribolet N., Carrel S., Bigner D. D. Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts. Cancer Res. 1988 Oct 15;48(20):5701–5707. [PubMed] [Google Scholar]
  12. Delaloye B., Bischof-Delaloye A., Buchegger F., von Fliedner V., Grob J. P., Volant J. C., Pettavel J., Mach J. P. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest. 1986 Jan;77(1):301–311. doi: 10.1172/JCI112291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Derocq J. M., Casellas P., Laurent G., Ravel S., Vidal H., Jansen F. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins. J Immunol. 1988 Oct 15;141(8):2837–2843. [PubMed] [Google Scholar]
  14. Fishwild D. M., Staskawicz M. O., Wu H. M., Carroli S. F. Cytotoxicity against human peripheral blood mononuclear cells and T cell lines mediated by anti-T cell immunotoxins in the absence of added potentiator. Clin Exp Immunol. 1991 Dec;86(3):506–513. doi: 10.1111/j.1365-2249.1991.tb02961.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goff D. A., Carroll S. F. Substituted 2-iminothiolanes: reagents for the preparation of disulfide cross-linked conjugates with increased stability. Bioconjug Chem. 1990 Nov-Dec;1(6):381–386. doi: 10.1021/bc00006a003. [DOI] [PubMed] [Google Scholar]
  16. Hirsch R., Bluestone J. A., Bare C. V., Gress R. E. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice. Transplant Proc. 1991 Feb;23(1 Pt 1):270–271. [PubMed] [Google Scholar]
  17. Horwitz A. H., Chang C. P., Better M., Hellstrom K. E., Robinson R. R. Secretion of functional antibody and Fab fragment from yeast cells. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8678–8682. doi: 10.1073/pnas.85.22.8678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Huston J. S., Levinson D., Mudgett-Hunter M., Tai M. S., Novotný J., Margolies M. N., Ridge R. J., Bruccoleri R. E., Haber E., Crea R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988 Aug;85(16):5879–5883. doi: 10.1073/pnas.85.16.5879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jocelyn P. C. Spectrophotometric assay of thiols. Methods Enzymol. 1987;143:44–67. doi: 10.1016/0076-6879(87)43013-9. [DOI] [PubMed] [Google Scholar]
  20. Johnston S., Lee J. H., Ray D. S. High-level expression of M13 gene II protein from an inducible polycistronic messenger RNA. Gene. 1985;34(2-3):137–145. doi: 10.1016/0378-1119(85)90121-0. [DOI] [PubMed] [Google Scholar]
  21. Kernan N. A., Knowles R. W., Burns M. J., Broxmeyer H. E., Lu L., Lee H. M., Kawahata R. T., Scannon P. J., Dupont B. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin. J Immunol. 1984 Jul;133(1):137–146. [PubMed] [Google Scholar]
  22. Lei S. P., Lin H. C., Wang S. S., Callaway J., Wilcox G. Characterization of the Erwinia carotovora pelB gene and its product pectate lyase. J Bacteriol. 1987 Sep;169(9):4379–4383. doi: 10.1128/jb.169.9.4379-4383.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Plückthun A. Antibody engineering: advances from the use of Escherichia coli expression systems. Biotechnology (N Y) 1991 Jun;9(6):545–551. doi: 10.1038/nbt0691-545. [DOI] [PubMed] [Google Scholar]
  24. Robinson R. R., Chartier J., Jr, Chang C. P., Horwitz A. H., Better M. Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities. Hum Antibodies Hybridomas. 1991 Apr;2(2):84–93. [PubMed] [Google Scholar]
  25. Rostaing-Capaillon O., Casellas P. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain. Cancer Immunol Immunother. 1991;34(1):24–30. doi: 10.1007/BF01741320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Skerra A., Pfitzinger I., Plückthun A. The functional expression of antibody Fv fragments in Escherichia coli: improved vectors and a generally applicable purification technique. Biotechnology (N Y) 1991 Mar;9(3):273–278. doi: 10.1038/nbt0391-273. [DOI] [PubMed] [Google Scholar]
  27. Skerra A., Plückthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science. 1988 May 20;240(4855):1038–1041. doi: 10.1126/science.3285470. [DOI] [PubMed] [Google Scholar]
  28. Takkinen K., Laukkanen M. L., Sizmann D., Alfthan K., Immonen T., Vanne L., Kaartinen M., Knowles J. K., Teeri T. T. An active single-chain antibody containing a cellulase linker domain is secreted by Escherichia coli. Protein Eng. 1991 Oct;4(7):837–841. doi: 10.1093/protein/4.7.837. [DOI] [PubMed] [Google Scholar]
  29. Trown P. W., Reardan D. T., Carroll S. F., Stoudemire J. B., Kawahata R. T. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain. Cancer Res. 1991 Aug 15;51(16):4219–4225. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES